Peter Marks (Jim Lo Scalzo/Pool via AP Images)

FDA's CBER chief hints at ex­pand­ing Sarep­ta's gene ther­a­py la­bel, sends stock up 25%

De­spite a failed con­fir­ma­to­ry tri­al an­nounced in Oc­to­ber, the FDA’s Pe­ter Marks, the top reg­u­la­tor for all cell and gene ther­a­pies in the US, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.